Controlled release of BMP-2 using a heparin-conjugated carrier system reduces in vivo adipose tissue formation

Jung Seok Lee, Sun Kyoung Lee, Byung Soo Kim, Gun Il Im, Kyoo Sung Cho, ChangSung Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

There is growing concern about unwanted effects associated with the clinical use of recombinant human bone morphogenetic protein-2 (rhBMP-2) at high concentrations, including cyst-like bone formation and excessive fatty marrow formation. We, therefore, evaluated the induction of mineralized/adipose tissue formation and the bone-healing pattern associated with the controlled release of E. coli-derived rhBMP-2 (ErhBMP-2) by a heparin-conjugated fibrin (HCF) system using ectopic and orthotopic in vivo models, respectively. In the ectopic transplantation model, mineralized tissue formed at the most superficial layer of the transplanted area and on the surfaces of grafted materials, and most of the interstitial space within the transplanted area was filled with excessive adipose tissue specifically at sites that received ErhBMP-2. However, sites that received ErhBMP-2 and HCF showed significantly increased mineralized tissue formation and decreased adipose tissue formation compared to the normal fibrin system with ErhBMP-2. In the orthotopic (calvarial defect) model, controlled release of ErhBMP-2 induced by HCF significantly reduced adipose tissue formation within the defect area compared to the clinically approved absorbable collagen sponge. From these results, it can be concluded that the use of a HCF system loaded with ErhBMP-2 may reduce adipose tissue formation and enhance mineralized tissue formation.

Original languageEnglish
Pages (from-to)545-554
Number of pages10
JournalJournal of Biomedical Materials Research - Part A
Volume103
Issue number2
DOIs
Publication statusPublished - 2015 Feb 1

Fingerprint

Heparin
Tissue
Fibrin
Bone
Proteins
Defects
Collagen
Escherichia coli

All Science Journal Classification (ASJC) codes

  • Ceramics and Composites
  • Biomaterials
  • Biomedical Engineering
  • Metals and Alloys

Cite this

Lee, Jung Seok ; Lee, Sun Kyoung ; Kim, Byung Soo ; Im, Gun Il ; Cho, Kyoo Sung ; Kim, ChangSung. / Controlled release of BMP-2 using a heparin-conjugated carrier system reduces in vivo adipose tissue formation. In: Journal of Biomedical Materials Research - Part A. 2015 ; Vol. 103, No. 2. pp. 545-554.
@article{bd212d3d05774f5892a49a721c286c58,
title = "Controlled release of BMP-2 using a heparin-conjugated carrier system reduces in vivo adipose tissue formation",
abstract = "There is growing concern about unwanted effects associated with the clinical use of recombinant human bone morphogenetic protein-2 (rhBMP-2) at high concentrations, including cyst-like bone formation and excessive fatty marrow formation. We, therefore, evaluated the induction of mineralized/adipose tissue formation and the bone-healing pattern associated with the controlled release of E. coli-derived rhBMP-2 (ErhBMP-2) by a heparin-conjugated fibrin (HCF) system using ectopic and orthotopic in vivo models, respectively. In the ectopic transplantation model, mineralized tissue formed at the most superficial layer of the transplanted area and on the surfaces of grafted materials, and most of the interstitial space within the transplanted area was filled with excessive adipose tissue specifically at sites that received ErhBMP-2. However, sites that received ErhBMP-2 and HCF showed significantly increased mineralized tissue formation and decreased adipose tissue formation compared to the normal fibrin system with ErhBMP-2. In the orthotopic (calvarial defect) model, controlled release of ErhBMP-2 induced by HCF significantly reduced adipose tissue formation within the defect area compared to the clinically approved absorbable collagen sponge. From these results, it can be concluded that the use of a HCF system loaded with ErhBMP-2 may reduce adipose tissue formation and enhance mineralized tissue formation.",
author = "Lee, {Jung Seok} and Lee, {Sun Kyoung} and Kim, {Byung Soo} and Im, {Gun Il} and Cho, {Kyoo Sung} and ChangSung Kim",
year = "2015",
month = "2",
day = "1",
doi = "10.1002/jbm.a.35207",
language = "English",
volume = "103",
pages = "545--554",
journal = "Journal of Biomedical Materials Research",
issn = "1549-3296",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

Controlled release of BMP-2 using a heparin-conjugated carrier system reduces in vivo adipose tissue formation. / Lee, Jung Seok; Lee, Sun Kyoung; Kim, Byung Soo; Im, Gun Il; Cho, Kyoo Sung; Kim, ChangSung.

In: Journal of Biomedical Materials Research - Part A, Vol. 103, No. 2, 01.02.2015, p. 545-554.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Controlled release of BMP-2 using a heparin-conjugated carrier system reduces in vivo adipose tissue formation

AU - Lee, Jung Seok

AU - Lee, Sun Kyoung

AU - Kim, Byung Soo

AU - Im, Gun Il

AU - Cho, Kyoo Sung

AU - Kim, ChangSung

PY - 2015/2/1

Y1 - 2015/2/1

N2 - There is growing concern about unwanted effects associated with the clinical use of recombinant human bone morphogenetic protein-2 (rhBMP-2) at high concentrations, including cyst-like bone formation and excessive fatty marrow formation. We, therefore, evaluated the induction of mineralized/adipose tissue formation and the bone-healing pattern associated with the controlled release of E. coli-derived rhBMP-2 (ErhBMP-2) by a heparin-conjugated fibrin (HCF) system using ectopic and orthotopic in vivo models, respectively. In the ectopic transplantation model, mineralized tissue formed at the most superficial layer of the transplanted area and on the surfaces of grafted materials, and most of the interstitial space within the transplanted area was filled with excessive adipose tissue specifically at sites that received ErhBMP-2. However, sites that received ErhBMP-2 and HCF showed significantly increased mineralized tissue formation and decreased adipose tissue formation compared to the normal fibrin system with ErhBMP-2. In the orthotopic (calvarial defect) model, controlled release of ErhBMP-2 induced by HCF significantly reduced adipose tissue formation within the defect area compared to the clinically approved absorbable collagen sponge. From these results, it can be concluded that the use of a HCF system loaded with ErhBMP-2 may reduce adipose tissue formation and enhance mineralized tissue formation.

AB - There is growing concern about unwanted effects associated with the clinical use of recombinant human bone morphogenetic protein-2 (rhBMP-2) at high concentrations, including cyst-like bone formation and excessive fatty marrow formation. We, therefore, evaluated the induction of mineralized/adipose tissue formation and the bone-healing pattern associated with the controlled release of E. coli-derived rhBMP-2 (ErhBMP-2) by a heparin-conjugated fibrin (HCF) system using ectopic and orthotopic in vivo models, respectively. In the ectopic transplantation model, mineralized tissue formed at the most superficial layer of the transplanted area and on the surfaces of grafted materials, and most of the interstitial space within the transplanted area was filled with excessive adipose tissue specifically at sites that received ErhBMP-2. However, sites that received ErhBMP-2 and HCF showed significantly increased mineralized tissue formation and decreased adipose tissue formation compared to the normal fibrin system with ErhBMP-2. In the orthotopic (calvarial defect) model, controlled release of ErhBMP-2 induced by HCF significantly reduced adipose tissue formation within the defect area compared to the clinically approved absorbable collagen sponge. From these results, it can be concluded that the use of a HCF system loaded with ErhBMP-2 may reduce adipose tissue formation and enhance mineralized tissue formation.

UR - http://www.scopus.com/inward/record.url?scp=84924423247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924423247&partnerID=8YFLogxK

U2 - 10.1002/jbm.a.35207

DO - 10.1002/jbm.a.35207

M3 - Article

C2 - 24764177

AN - SCOPUS:84924423247

VL - 103

SP - 545

EP - 554

JO - Journal of Biomedical Materials Research

JF - Journal of Biomedical Materials Research

SN - 1549-3296

IS - 2

ER -